Highlander Capital Management, LLC Bluebird Bio, Inc. Transaction History

Highlander Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$8.96 - $16.31 $10,752 - $19,572	-1,200 Reduced 70.59%	500 $5,000
Q2 2021 Aug 10, 2021	SELL	$18.04 - $22.09 $7,216 - $8,836	-400 Reduced 19.05%	1,700 $54,000
Q1 2021 May 14, 2021	BUY	$16.59 - $33.89 $9,954 - $20,334	600 Added 40.0%	2,100 $63,000
Q4 2020 Feb 12, 2021	SELL	$27.5 - $37.92 $19,250 - $26,544	-700 Reduced 31.82%	1,500 $65,000
Q3 2020 Nov 17, 2020	BUY	$34.44 - $43.75 $24,108 - $30,625	700 Added 46.67%	2,200 $119,000
Q1 2020 May 27, 2020	SELL	$26.16 - $63.5 $10,464 - $25,400	-400 Reduced 21.05%	1,500 $69,000
Q4 2019 Feb 13, 2020	BUY	$46.96 - $61.67 $18,784 - $24,668	400 Added 26.67%	1,900 $167,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $22,752 - $31,562	-300 Reduced 16.67%	1,500 $191,000
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $19,332 - $31,233	300 Added 20.0%	1,800 $283,000
Q3 2017 Nov 15, 2017	BUY	$57.74 - $91.42 $86,610 - $137,130	1,500	1,500 $206,000

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Highlander Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Highlander Capital Management, LLC with notifications on news.